Pfiz­er sweeps out a line­up of neu­ro­science drugs — as well as can­cer and NASH pro­grams — in­to the scrap heap

Any­one shop­ping for some ear­ly- and mid-stage neu­ro­sciences pro­grams should look over the menu of dis­con­tin­ued pro­grams out from Pfiz­er $PFE this morn­ing. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Senior Associate - Life Science

Alexandria Real Estate Equities

Seattle, WA, USA